PubMed

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.

Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E.

Ann Intern Med. 1998 Dec 15;129(12):1027-30.PMID: 9867757 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E.

Clin Pharmacol Ther. 2001 Mar;69(3):158-68.PMID: 11240980 [PubMed - indexed for MEDLINE]Related articles

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.

Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T.

J Gastroenterol Hepatol. 2002 Jul;17(7):748-53.PMID: 12121503 [PubMed - indexed for MEDLINE]Related articles

Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.

Furuta T, Takashima M, Shirai N, Xiao F, Hanai H, Ohashi K, Ishizaki T.

Clin Pharmacol Ther. 2000 Jun;67(6):684-9. Review.PMID: 10872651 [PubMed - indexed for MEDLINE]Related articles

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.

Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K, Sugimura H, Ohashi K, Ishizaki T.

Pharmacogenetics. 2001 Jun;11(4):341-8.PMID: 11434512 [PubMed - indexed for MEDLINE]Related articles

CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.

Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M, Okumura K.

Clin Pharmacol Ther. 1999 Nov;66(5):528-34.PMID: 10579481 [PubMed - indexed for MEDLINE]Related articles

Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.

Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M.

Dig Liver Dis. 2001 Nov;33(8):671-5.PMID: 11785712 [PubMed - indexed for MEDLINE]Related articles

Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.

Aoyama N, Tanigawara Y, Kita T, Sakai T, Shirakawa K, Shirasaka D, Kodama F, Okumura K, Kasuga M.

J Gastroenterol. 1999;34 Suppl 11:80-3.PMID: 10616772 [PubMed - indexed for MEDLINE]Related articles

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.

Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.

Am J Gastroenterol. 2003 Nov;98(11):2403-8.PMID: 14638340 [PubMed - indexed for MEDLINE]Related articles

A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.

Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, Tsuji T.

J Gastroenterol Hepatol. 2001 Jul;16(7):723-8.PMID: 11446878 [PubMed - indexed for MEDLINE]Related articles

CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.

Sagar M, Seensalu R, Tybring G, Dahl ML, Bertilsson L.

Scand J Gastroenterol. 1998 Oct;33(10):1034-8.PMID: 9829356 [PubMed - indexed for MEDLINE]Related articles

The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.

Sapone A, Vaira D, Trespidi S, Perna F, Gatta L, Tampieri A, Ricci C, Cantelli-Forti G, Miglioli M, Biagi GL, Paolini M.

Am J Gastroenterol. 2003 May;98(5):1010-5.PMID: 12809821 [PubMed - indexed for MEDLINE]Related articles

Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.

Sheu BS, Kao AW, Cheng HC, Hunag SF, Chen TW, Lu CC, Wu JJ.

Aliment Pharmacol Ther. 2005 Feb 1;21(3):283-8.PMID: 15691303 [PubMed - indexed for MEDLINE]Related articlesFree article

Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis.

Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N.

Dig Dis Sci. 2001 Nov;46(11):2445-50.PMID: 11713950 [PubMed - indexed for MEDLINE]Related articles

[Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese]

He XX, Zhao YH, Hao YT.

Zhonghua Nei Ke Za Zhi. 2004 Jan;43(1):13-5. Chinese. PMID: 14990013 [PubMed - indexed for MEDLINE]Related articles

High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.

Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T.

Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.PMID: 14696516 [PubMed - indexed for MEDLINE]Related articles

Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.

Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T, Droździk M.

Eur J Clin Pharmacol. 2006 Oct;62(10):877-80. Epub 2006 Aug 16.PMID: 16912869 [PubMed - indexed for MEDLINE]Related articles

Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.

Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):375-9. Epub 2005 Jun 23.PMID: 15976989 [PubMed - indexed for MEDLINE]Related articles

Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.

Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kobayashi M, Oyasu K, Hayakumo T, Mizuno S, Kiyota K, Nakajima M, Kimoto K, Inokuchi H, Kawai K.

Aliment Pharmacol Ther. 2003 Jan;17(2):259-64.PMID: 12534411 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.

Hokari K, Sugiyama T, Kato M, Saito M, Miyagishima T, Kudo M, Nishikawa K, Ishizuka J, Komatsu Y, Mizushima T, Kagaya H, Hige S, Takeda H, Asaka M.

Aliment Pharmacol Ther. 2001 Sep;15(9):1479-84.PMID: 11552922 [PubMed - indexed for MEDLINE]Related articlesFree article